The PASS questionnaire demonstrated excellent test-retest reliability when comparing questionnaire scores from the baseline visit with those obtained one week later. It also demonstrated good responsiveness in detecting a significant change in health status. Because the PASS test questionnaire was designed to pose a very limited number of questions – each question intended to address an independent aspect of the patient’s symptoms – there was, as expected, low internal consistency and this was confirmed by the G-analysis.
Approximately 30% of the patients reported complete resolution of their symptoms, based on their PASS and GOS scores. Because this was an open label treatment study, one cannot conclude that esomeprazole was superior to the previous PPI therapy but the data suggest that persistent symptoms will respond to a change in PPI therapy in a substantial proportion of patients. Further, double-blind studies are needed to determine the extent to which more potent acid suppression will produce symptom resolution in patients with persistent symptoms on standard PPI therapy. The present paper presents the development and validation of a short, five-question tool to identify patients with persistent acid-related symptoms; test scores correlate well with accepted validated scales and the new, short questionnaire shows a good response to a four-week course of acid suppression therapy with a PPI. Time to visit a trusted pharmacy – buy ortho tri-cyclen to begin your treatment now.